(Q44048384)

29 November 2017

title

Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen (English)

1 reference

29 November 2017

author

Frederick R. Appelbaum

9

object named as

F Appelbaum

1 reference

29 November 2017

F Gutierrez-Delgado

1

1 reference

29 November 2017

L Holmberg

2

1 reference

29 November 2017

H Hooper

3

1 reference

29 November 2017

S Petersdorf

4

1 reference

29 November 2017

O Press

5

1 reference

29 November 2017

R Maziarz

6

1 reference

29 November 2017

D Maloney

7

1 reference

29 November 2017

T Chauncey

8

1 reference

29 November 2017

W Bensinger

10

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

Bone Marrow Transplantation

29 November 2017

published in

1 reference

29 November 2017

volume

32

1 reference

29 November 2017

issue

3

1 reference

29 November 2017

page(s)

279-285

1 reference

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

Interleukin-2 +/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease: retrospective analysis of 158 cases from the French registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

7 January 2021

Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

7 January 2021

High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease--a 6-year update

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

7 January 2021

High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

7 January 2021

One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

7 January 2021

High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

7 January 2021

Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

7 January 2021

Factors that influence collection and engraftment of autologous peripheral-blood stem cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

7 January 2021

High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

7 January 2021

Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

7 January 2021

Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

7 January 2021

Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): comparative results with two CBV regimens and importance of disease status at transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704110

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704110

1 reference

29 November 2017

1 reference